ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
Article Details
- CitationCopy to clipboard
Fizazi K, Albiges L, Loriot Y, Massard C
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
Expert Rev Anticancer Ther. 2015;15(9):1007-17. doi: 10.1586/14737140.2015.1081566.
- PubMed ID
- 26313416 [ View in PubMed]
- Abstract
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ketodarolutamide Androgen receptor Protein Humans UnknownAntagonistDetails